GSA Capital Partners LLP reduced its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) by 9.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 493,571 shares of the company’s stock after selling 50,667 shares during the period. GSA Capital Partners LLP owned 0.67% of Protalix BioTherapeutics worth $622,000 at the end of the most recent reporting period.
Separately, Bailard Inc. bought a new position in shares of Protalix BioTherapeutics during the fourth quarter valued at approximately $121,000. 16.53% of the stock is owned by institutional investors.
Protalix BioTherapeutics Stock Performance
Shares of NYSE PLX opened at $1.14 on Friday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.09. The company has a 50 day simple moving average of $1.16 and a two-hundred day simple moving average of $1.34. The company has a market capitalization of $83.58 million, a price-to-earnings ratio of 28.50 and a beta of 0.78.
Protalix BioTherapeutics Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
Featured Stories
- Five stocks we like better than Protalix BioTherapeutics
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 7/8 – 7/12
- There Are Different Types of Stock To Invest In
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
Want to see what other hedge funds are holding PLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report).
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.